+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Immuno-Oncology Market by Therapy Type (Cancer Vaccines, Cell Therapy, Checkpoint Inhibitors), Indication (Breast Cancer, Colorectal Cancer, Lung Cancer), End User, Line Of Therapy, Mechanism - Global Forecast 2025-2030- Product Image
Immuno-Oncology Market by Therapy Type (Cancer Vaccines, Cell Therapy, Checkpoint Inhibitors), Indication (Breast Cancer, Colorectal Cancer, Lung Cancer), End User, Line Of Therapy, Mechanism - Global Forecast 2025-2030- Product Image
Sale

Immuno-Oncology Market by Therapy Type (Cancer Vaccines, Cell Therapy, Checkpoint Inhibitors), Indication (Breast Cancer, Colorectal Cancer, Lung Cancer), End User, Line Of Therapy, Mechanism - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5889363
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The immuno-oncology market is rapidly evolving as novel therapies, focused alliances, and adaptive frameworks reshape the competitive landscape. This report empowers senior decision-makers to anticipate growth drivers and better navigate supply chain complexity, shifting regulations, and emerging therapeutic modalities.

Market Snapshot: Immuno-Oncology Market Size and Growth Prospects

The Immuno-Oncology Market grew from USD 5.89 billion in 2024 to USD 6.51 billion in 2025. It is expected to continue growing at a CAGR of 10.03%, reaching USD 10.46 billion by 2030. Recent years have witnessed accelerated innovation, broadening the market’s scope, and prompting new commercialization strategies as investment escalates. Diverse therapy platforms and emerging regulatory approaches are influencing stakeholder priorities globally.

Scope & Segmentation of the Immuno-Oncology Market

This report presents detailed segmentation and regional analysis to clarify key focus areas for market participants:

  • Therapy Types: Cancer vaccines (including dendritic cell, DNA, and peptide vaccines), cell therapies such as CAR-T (allogeneic and autologous), NK cell therapies, TCR-T therapies, checkpoint inhibitors (CTLA-4, PD-1, PD-L1), cytokines, and oncolytic viruses.
  • Indications: Breast cancer (HER2-positive and triple-negative), colorectal cancer, lung cancers (NSCLC and small cell), lymphoma, melanoma (cutaneous and uveal).
  • End Users: Academic institutes, cancer research institutes, clinics, hospitals.
  • Lines of Therapy: First line, second line, third line, fourth line or beyond.
  • Mechanisms of Action: Active immunotherapy (such as cancer vaccines and cytokine-based therapy) and passive immunotherapy (including adoptive cell transfer, checkpoint inhibitors, monoclonal antibodies).
  • Regions Covered: Americas (with detailed state-level focus), Europe, Middle East & Africa (including leading and emerging markets), and Asia-Pacific (covering major countries and fast-growing healthcare hubs).
  • Company Analysis: Coverage includes Bristol-Myers Squibb Company, Merck & Co., Inc., Roche Holding AG, AstraZeneca PLC, Gilead Sciences, Inc., Novartis AG, Amgen Inc., Pfizer Inc., Eli Lilly and Company, and Johnson & Johnson.

Key Takeaways for Senior Decision-Makers

  • Breakthroughs in immuno-oncology continue to shift cancer treatment paradigms, with cellular and checkpoint-based therapies broadening the spectrum of available options.
  • Strategic partnerships involving academic, biotech, and regulatory stakeholders are accelerating clinical validation and enabling adaptive regulatory approvals.
  • Differentiated care models, including digital health platforms and biomarker-driven monitoring, are enhancing patient stratification and supporting value-based care initiatives.
  • Operational efficiency is increasingly reliant on real-world evidence, robust manufacturing scale-up, and efficient supply-chain strategies to minimize delays and cost volatility.
  • Companies are gaining competitive advantage through agile commercialization, integrated R&D, and strategic acquisitions focused on pipeline diversification and expansion into high-value segments.

Tariff Impact: Supply Chain and International Partnerships

Anticipated United States tariffs on biologic components and specialized equipment in 2025 will introduce cost pressures throughout the immuno-oncology value chain. Organizations are actively reassessing sourcing strategies, including near-shoring and domestic vendor agreements, to maintain operational resilience. These tariffs are expected to influence cross-border collaboration models and shape global site selection for clinical trials, underscoring the need for proactive mitigation plans that support both current project timelines and future growth objectives.

Methodology & Data Sources

The research integrates in-depth interviews with oncologists, trial leaders, executives, and regulatory experts, triangulated with global clinical trial databases and regulatory filings. Supplementary secondary analysis incorporates peer-reviewed literature, white papers, financial disclosures, and scenario modeling. This robust approach ensures validated insights and actionable perspectives for stakeholders.

The Immuno-Oncology Market: Why This Report Matters

  • Enables executive teams to assess opportunity sizing, risk factors, and emerging competitors in specialized therapeutic segments.
  • Guides strategic planning with a complete view of therapy trends, regulatory frameworks, and supply-chain vulnerabilities—with recommendations on resource prioritization.
  • Equips decision-makers with the insight needed to align commercialization strategies, foster strategic alliances, and target high-growth geographies or product categories.

Conclusion

Immuno-oncology stands at the intersection of advanced science, regulatory evolution, and data-driven decision-making. Stakeholders who act on data-rich insights and anticipate changing market requirements will be well-placed to unlock new growth potential in this dynamic arena.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of next-generation bispecific T-cell engagers to improve tumor targeting and reduce off-target toxicity
5.2. Expansion of personalized neoantigen vaccine pipelines leveraging AI-driven epitope prediction for solid tumors
5.3. Advancement of CAR-NK therapies incorporating gene edits to overcome tumor microenvironment immunosuppression
5.4. Adoption of real-world evidence and digital biomarkers to measure immunotherapy response and patient stratification at scale
5.5. Emergence of microbiome-modulating adjuvants to enhance checkpoint inhibitor efficacy in resistant cancer subtypes
5.6. Development of dual-targeting ADC conjugates combining immune checkpoint blockade with tumor-specific cytotoxic payloads
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Immuno-Oncology Market, by Therapy Type
8.1. Introduction
8.2. Cancer Vaccines
8.2.1. Cancer Vaccines
8.2.1.1. Dendritic Cell Vaccines
8.2.1.2. DNA Vaccines
8.2.1.3. Peptide Vaccines
8.3. Cell Therapy
8.3.1. CAR-T Therapy
8.3.1.1. Allogeneic
8.3.1.2. Autologous
8.3.2. NK Cell Therapy
8.3.3. TCR-T Therapy
8.4. Checkpoint Inhibitors
8.4.1. CTLA-4 Inhibitors
8.4.2. PD-1 Inhibitors
8.4.3. PD-L1 Inhibitors
8.5. Cytokines
8.6. Oncolytic Viruses
9. Immuno-Oncology Market, by Indication
9.1. Introduction
9.2. Breast Cancer
9.2.1. Her2-Positive Breast Cancer
9.2.2. Triple-Negative Breast Cancer
9.3. Colorectal Cancer
9.4. Lung Cancer
9.4.1. Nsclc
9.4.2. Small Cell Lung Cancer
9.5. Lymphoma
9.6. Melanoma
9.6.1. Cutaneous Melanoma
9.6.2. Uveal Melanoma
10. Immuno-Oncology Market, by End User
10.1. Introduction
10.2. Academic Institutes
10.3. Cancer Research Institutes
10.4. Clinics
10.5. Hospitals
11. Immuno-Oncology Market, by Line Of Therapy
11.1. Introduction
11.2. First Line
11.3. Fourth Line Or Beyond
11.4. Second Line
11.5. Third Line
12. Immuno-Oncology Market, by Mechanism
12.1. Introduction
12.2. Active Immunotherapy
12.2.1. Cancer Vaccines
12.2.2. Cytokine-Based Therapy
12.3. Passive Immunotherapy
12.3.1. Adoptive Cell Transfer
12.3.1.1. CAR-T Therapy
12.3.1.2. TCR-T Therapy
12.3.2. Checkpoint Inhibitors
12.3.3. Monoclonal Antibodies
13. Americas Immuno-Oncology Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Immuno-Oncology Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Immuno-Oncology Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Bristol-Myers Squibb Company
16.3.2. Merck & Co., Inc.
16.3.3. Roche Holding AG
16.3.4. AstraZeneca PLC
16.3.5. Gilead Sciences, Inc.
16.3.6. Novartis AG
16.3.7. Amgen Inc.
16.3.8. Pfizer Inc.
16.3.9. Eli Lilly and Company
16.3.10. Johnson & Johnson
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. IMMUNO-ONCOLOGY MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. IMMUNO-ONCOLOGY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. IMMUNO-ONCOLOGY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. IMMUNO-ONCOLOGY MARKET: RESEARCHAI
FIGURE 26. IMMUNO-ONCOLOGY MARKET: RESEARCHSTATISTICS
FIGURE 27. IMMUNO-ONCOLOGY MARKET: RESEARCHCONTACTS
FIGURE 28. IMMUNO-ONCOLOGY MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. IMMUNO-ONCOLOGY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY DENDRITIC CELL VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY DNA VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PEPTIDE VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TCR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TCR-T THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CYTOKINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ONCOLYTIC VIRUSES, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ONCOLYTIC VIRUSES, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HER2-POSITIVE BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HER2-POSITIVE BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TRIPLE-NEGATIVE BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TRIPLE-NEGATIVE BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NSCLC, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY NSCLC, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CUTANEOUS MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CUTANEOUS MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY UVEAL MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY UVEAL MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FOURTH LINE OR BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY FOURTH LINE OR BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CYTOKINE-BASED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CYTOKINE-BASED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TCR-T THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY TCR-T THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS IMMUNO-ONCOLOGY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES IMMUNO-ONCOLOGY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 199. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 200. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 201. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 202. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 203. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 204. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 205. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 206. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 207. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2024 (USD MILLION)
TABLE 208. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2025-2030 (USD MILLION)
TABLE 209. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 210. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 211. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 212. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 213. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 214. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 215. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 216. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 217. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 218. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 219. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 222. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 223. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 224. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 225. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 226. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 227. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 228. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 229. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2024 (USD MILLION)
TABLE 230. CANADA IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2025-2030 (USD MILLION)
TABLE 231. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 232. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 233. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 234. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 235. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 236. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 237. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 238. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 239. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2024 (USD MILLION)
TABLE 240. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2025-2030 (USD MILLION)
TABLE 241. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 242. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 243. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 244. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 245. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 246. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 247. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 248. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 249. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 250. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 251. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 252. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 253. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 254. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 255. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 256. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 257. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 258. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 259. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 260. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 261. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2024 (USD MILLION)
TABLE 262. MEXICO IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2025-2030 (USD MILLION)
TABLE 263. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 264. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 265. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 266. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 267. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 268. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 271. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2024 (USD MILLION)
TABLE 272. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2025-2030 (USD MILLION)
TABLE 273. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 274. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 275. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 276. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 277. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 278. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 279. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 280. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 281. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 282. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 283. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 284. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 285. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 286. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 287. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 288. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 289. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 290. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 291. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 292. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 293. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2024 (USD MILLION)
TABLE 294. BRAZIL IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2025-2030 (USD MILLION)
TABLE 295. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 296. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 297. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 298. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 299. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 300. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 301. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 302. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 303. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2024 (USD MILLION)
TABLE 304. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2025-2030 (USD MILLION)
TABLE 305. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 306. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 307. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 308. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 309. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 310. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 311. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 312. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 313. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 314. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2025-2030 (USD MILLION)
TABLE 315. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 316. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 317. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 318. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 319. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2018-2024 (USD MILLION)
TABLE 320. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY MECHANISM, 2025-2030 (USD MILLION)
TABLE 321. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 322. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 323. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2018-2024 (USD MILLION)
TABLE 324. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, 2025-2030 (USD MILLION)
TABLE 325. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2018-2024 (USD MILLION)
TABLE 326. ARGENTINA IMMUNO-ONCOLOGY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, 2025-2030 (USD MILLION)
TABLE 327. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 328. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 329. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 330. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 331. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2018-2024 (USD MILLION)
TABLE 332. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CANCER VACCINES, 2025-2030 (USD MILLION)
TABLE 333. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
TABLE 334. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CELL THERAPY, 2025-2030 (USD MILLION)
TABLE 335. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2018-2024 (USD MILLION)
TABLE 336. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CAR-T THERAPY, 2025-2030 (USD MILLION)
TABLE 337. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2024 (USD MILLION)
TABLE 338. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2025-2030 (USD MILLION)
TABLE 339. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 340. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 341. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2018-2024 (USD MILLION)
TABLE 342. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY BREAST CANCER, 2025-2030 (USD MILLION)
TABLE 343. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 344. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 345. EUROPE, MIDDLE EAST & AFRICA IMMUNO-ONCOLOGY MARKET SIZE, BY MELANOMA, 2018-2024 (USD MILLION)
TABLE 346. EUROPE, MIDDLE EAST & A

Samples

Loading
LOADING...

Companies Mentioned

The major companies profiled in this Immuno-Oncology market report include:
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • Roche Holding AG
  • AstraZeneca PLC
  • Gilead Sciences, Inc.
  • Novartis AG
  • Amgen Inc.
  • Pfizer Inc.
  • Eli Lilly and Company
  • Johnson & Johnson

Table Information

Report AttributeDetails
No. of Pages184
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 6.51 Billion
Forecasted Market Value ( USD ) by 2030 $ 10.46 Billion
Compound Annual Growth Rate10.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Immuno-oncology Clinical Trials Market by Therapy Type (Adoptive Cell Therapies, Cancer Vaccines, Checkpoint Inhibitors), Trial Phase (Phase I, Phase Ii, Phase Iii), Indication, Sponsor Type, Trial Type, Patient Enrollment - Global Forecast 2025-2030 - Product Image

Immuno-oncology Clinical Trials Market by Therapy Type (Adoptive Cell Therapies, Cancer Vaccines, Checkpoint Inhibitors), Trial Phase (Phase I, Phase Ii, Phase Iii), Indication, Sponsor Type, Trial Type, Patient Enrollment - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Immuno-Oncology Service Market by Therapy Type (Cancer Vaccines, Car-T Therapy, Checkpoint Inhibitors), Cancer Indication (Breast Cancer, Leukemia, Lung Cancer), End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Immuno-Oncology Service Market by Therapy Type (Cancer Vaccines, Car-T Therapy, Checkpoint Inhibitors), Cancer Indication (Breast Cancer, Leukemia, Lung Cancer), End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Precision Immuno-Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Precision Immuno-Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Immuno-Oncology - Global Strategic Business Report - Product Image

Immuno-Oncology - Global Strategic Business Report

  • Report
  • 224 Pages
  • Global
From
Immuno-Oncology Drugs Market Report 2025 - Product Image

Immuno-Oncology Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.